國際研究確認：NT-proBNP測試對急性心衰竭診斷和預後評估的重要性

本翻譯僅作學術交流用，無商業意圖，請勿轉載，如有疑議問請來信

這項跨越三大洲的國際研究聚焦於1256名病患，探討了NT-proBNP在急性心衰竭診斷和短期預後評估中的應用。研究發現，急性心衰竭患者的NT-proBNP中位數顯著高於非心衰竭患者（4639對108 pg/mL），且其水平與心衰竭症狀嚴重度呈正相關。根據年齡設定的NT-proBNP閾值可有效診斷急性心衰竭，且NT-proBNP水平超過5180 pg/mL的患者，其76天內死亡風險顯著提高。此研究為使用NT-proBNP於呼吸困難患者中設立了更廣泛的標準。

NT-proBNP檢測用於診斷和急性不穩定心力衰竭的短期預後：對1256名患者的國際合併分析：國際NT-proBNP合作研究

NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study

James L Januzzi 1, Roland van Kimmenade, John Lainchbury, Antoni Bayes-Genis, Jordi Ordonez-Llanos, Miguel Santalo-Bel, Yigal M Pinto, Mark Richards
Affiliations expand
PMID: 16293638 DOI: 10.1093/eurheartj/ehi631

https://pubmed.ncbi.nlm.nih.gov/16293638/

Abstract

Experience with amino-terminal pro-brain natriuretic peptide (NT-proBNP) testing for evaluation of dyspnoeic patients with suspected acute heart failure (HF) is limited to single-centre studies. We wished to establish broader standards for NT-proBNP testing in a study involving four sites in three continents.

Differences in NT-proBNP levels among 1256 patients with and without acute HF and the relationship between NT-proBNP levels and HF symptoms were examined. Optimal cut-points for diagnosis and prognosis were identified and verified using bootstrapping and multi-variable logistic regression techniques. Seven hundred and twenty subjects (57.3%) had acute HF, whose median NT-proBNP was considerably higher than those without (4639 vs. 108 pg/mL, P<0.001), and levels of NT-proBNP correlated with HF symptom severity (P=0.008). An optimal strategy to identify acute HF was to use age-related cut-points of 450, 900, and 1800 pg/mL for ages <50, 50-75, and >75, which yielded 90% sensitivity and 84% specificity for acute HF. An age-independent cut-point of 300 pg/mL had 98% negative predictive value to exclude acute HF. Among those with acute HF, a presenting NT-proBNP concentration >5180 pg/mL was strongly predictive of death by 76 days [odds ratio=5.2, 95% confidence interval (CI)=2.2-8.1, P<0.001].

In this multi-centre, international study, NT-proBNP testing was valuable for diagnostic evaluation and short-term prognosis estimation in dyspnoeic subjects with suspected or confirmed acute HF and should establish broader standards for use of the NT-proBNP in dyspnoeic patients.

摘要

Experience with amino-terminal pro-brain natriuretic peptide (NT-proBNP) testing for evaluation of dyspnoeic patients with suspected acute heart failure (HF) is limited to single-centre studies. We wished to establish broader standards for NT-proBNP testing in a study involving four sites in three continents.

Differences in NT-proBNP levels among 1256 patients with and without acute HF and the relationship between NT-proBNP levels and HF symptoms were examined. Optimal cut-points for diagnosis and prognosis were identified and verified using bootstrapping and multi-variable logistic regression techniques. Seven hundred and twenty subjects (57.3%) had acute HF, whose median NT-proBNP was considerably higher than those without (4639 vs. 108 pg/mL, P<0.001), and levels of NT-proBNP correlated with HF symptom severity (P=0.008). An optimal strategy to identify acute HF was to use age-related cut-points of 450, 900, and 1800 pg/mL for ages <50, 50-75, and >75, which yielded 90% sensitivity and 84% specificity for acute HF. An age-independent cut-point of 300 pg/mL had 98% negative predictive value to exclude acute HF. Among those with acute HF, a presenting NT-proBNP concentration >5180 pg/mL was strongly predictive of death by 76 days [odds ratio=5.2, 95% confidence interval (CI)=2.2-8.1, P<0.001].

在這項多中心國際研究中，NT-proBNP檢測對於疑似或確診急性HF的呼吸困難患者的診斷評估和短期預後估計非常有價值，應建立更廣泛的標準，以便在呼吸困難患者中使用NT-proBNP。